Company profile

Future of GlaxoSmithKline

#
Rank
46
| Quantumrun Global 1000

GlaxoSmithKline plc (abbreviated as GSK) is a British pharmaceutical company headquartered in Brentford, London. Founded in 2000 through the merger of SmithKline Beecham and Glaxo Wellcome, As of 2015, it was the world's 6th biggest pharmaceutical company, next to Pfizer, Novartis, Merck, Hoffmann-La Roche and Sanofi.

Home Country:
Sector:
Industry:
Pharmaceuticals
Founded:
1920
Global employee count:
99300
Domestic employee count:
17000
Number of domestic locations:
1

Financial Health

Revenue:
$27889000000 GBP
3y average revenue:
$24939333333 GBP
Operating expenses:
$16001000000 GBP
3y average expenses:
$10945000000 GBP
Funds in reserve:
$4897000000 GBP
Market country
Revenue from country
0.37

Asset Performance

  1. Product/Service/Dept. name
    Pharmaceuticals
    Product/Service revenue
    16104000000
  2. Product/Service/Dept. name
    Consumer healthcare
    Product/Service revenue
    7193000000
  3. Product/Service/Dept. name
    Vaccines
    Product/Service revenue
    4592000000

Innovation assets and Pipeline

Investment into R&D:
$3628000000 GBP

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.

COMPANY’S FUTURE PROSPECTS

Company Headlines